Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sucraid in Genetic Sucrase-Isomaltase Deficiency
NCT02784067Phase 4Withdrawn
- Sponsor
- QOL Medical
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Replacement Enzymes
01
Overview
Phase 4, randomised, double-blind trial of sacrosidase in Genetic sucrase-isomaltase deficiency (GSID) (2 arms), sponsored by QOL Medical. Primary endpoint: Response to Sucraid and placebo based on improvement in daily stool consistency up to 2 years. Planned start May 2016; status: withdrawn.
02
Drugs
sacrosidase
03
Conditions
Genetic sucrase-isomaltase deficiency (GSID)
Beyond the preview
Go deeper on NCT02784067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784067.